Tesh Khullar: How Community Oncologists Can Get Ahead of Changes in Reimbursement for Biosimilars

October 15, 2019

Practices are going to have to decide which biosimilar manufacturers they want to be able to partner with, explained Tesh Khullar, senior vice president & advisor, Flatiron Health.

Practices are going to have to decide which biosimilar manufacturers they want to be able to partner with, explained Tesh Khullar, senior vice president & advisor, Flatiron Health.

Transcript

What are some best strategies for community practices to stay ahead of market trends in biosimilar reimbursement?

I think practices are going to have to decide which manufacturers they want to be able to partner with. This is where I think the larger practices have an advantage, because if the biosimilar manufacturers do what Amgen did and Amgen went to the top 50 oncology groups in the nation, then you’re going to see other smaller practices not have access to the same level of rebates and discounting that the larger ones do. So, it does speak to the consolidation efforts, that if you’re not part of a larger consortium, you’re not going to be able to get the best price on biosimilars.